Yudong D He
Overview
Explore the profile of Yudong D He including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
6584
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Liu Y, Gao H, He Y
PLoS One
. 2020 Apr;
15(4):e0231252.
PMID: 32294131
Drug induced liver injury (DILI) is one of the key safety concerns in drug development. To assess the likelihood of drug candidates with potential adverse reactions of liver, we propose...
12.
Minocherhomji S, Liu Y, He Y, Fielden M
Environ Mol Mutagen
. 2020 Feb;
61(8):770-785.
PMID: 32078182
Genome instability is a hallmark of most human cancers and is exacerbated following replication stress. However, the effects that drugs/xenobiotics have in promoting genome instability including chromosomal structural rearrangements in...
13.
Baloni P, Sangar V, Yurkovich J, Robinson M, Taylor S, Karbowski C, et al.
Sci Rep
. 2019 Jul;
9(1):9807.
PMID: 31285465
Mapping network analysis in cells and tissues can provide insights into metabolic adaptations to changes in external environment, pathological conditions, and nutrient deprivation. Here, we reconstructed a genome-scale metabolic network...
14.
Taylor S, Ominsky M, Hu R, Pacheco E, He Y, Brown D, et al.
Bone
. 2016 Jan;
84:148-159.
PMID: 26721737
Inhibition of sclerostin with sclerostin antibody (Scl-Ab) has been shown to stimulate bone formation, decrease bone resorption, and increase bone mass in both animals and humans. To obtain insight into...
15.
Nioi P, Taylor S, Hu R, Pacheco E, He Y, Hamadeh H, et al.
J Bone Miner Res
. 2015 Feb;
30(8):1457-67.
PMID: 25678055
Sclerostin antibody (Scl-Ab) increases bone formation through a process dependent on the activation of canonical Wnt signaling, although the specific signaling in the osteoblast lineage in vivo is largely unknown....
16.
Li N, Oquendo E, Capaldi R, Robinson J, He Y, Hamadeh H, et al.
Toxicol Sci
. 2014 Aug;
142(1):261-73.
PMID: 25163676
Mitochondrial perturbation has been recognized as a contributing factor to various drug-induced organ toxicities. To address this issue, we developed a high-throughput flow cytometry-based mitochondrial signaling assay to systematically investigate...
17.
He Y, Karbowski C, Werner J, Everds N, Di Palma C, Chen Y, et al.
PLoS One
. 2014 Feb;
9(2):e88750.
PMID: 24551150
Gene expression profiling is a tool to gain mechanistic understanding of adverse effects in response to compound exposure. However, little is known about how the common handling procedures of experimental...
18.
Andrews D, Hamadeh H, He Y, Boren B, Turk J, Boyce R, et al.
Toxicol Pathol
. 2013 May;
42(3):540-54.
PMID: 23674392
We previously reported an increased incidence of thrombotic toxicities in Sprague-Dawley rats administered the highest dose level of a hyperglycosylated analog of recombinant human erythropoietin (AMG 114) for 1 month...
19.
Andrews D, Boren B, Turk J, Boyce R, He Y, Hamadeh H, et al.
Toxicol Pathol
. 2013 May;
42(3):524-39.
PMID: 23674391
We recently reported results that erythropoiesis-stimulating agent (ESA)-related thrombotic toxicities in preclinical species were not solely dependent on a high hematocrit (HCT) but also associated with increased ESA dose level,...
20.
Mongan M, Dunn R, Vonderfecht S, Everds N, Chen G, Su C, et al.
PLoS One
. 2011 Jan;
5(12):e15595.
PMID: 21203578
Genome-wide gene expression profiling has become standard for assessing potential liabilities as well as for elucidating mechanisms of toxicity of drug candidates under development. Analysis of microarray data is often...